These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Targeting the androgen receptor signaling pathway in advanced prostate cancer. Chung C, Abboud K. Am J Health Syst Pharm; 2022 Jul 22; 79(15):1224-1235. PubMed ID: 35390118 [Abstract] [Full Text] [Related]
23. Survival outcomes in older men with non-metastatic castration-resistant prostate cancer treated with androgen receptor inhibitors: a US Food and Drug Administration pooled analysis of patient-level data from three randomised trials. Fallah J, Zhang L, Amatya A, Gong Y, King-Kallimanis B, Bhatnagar V, Weinstock C, Suzman DL, Agrawal S, Chang E, Anscher MS, Chi DC, Xu JX, Brewer JR, Brave MH, Hadadi M, Theoret MR, Kluetz PG, Goldberg KB, Ibrahim A, Tang S, Pazdur R, Beaver JA, Amiri-Kordestani L, Singh H. Lancet Oncol; 2021 Sep 22; 22(9):1230-1239. PubMed ID: 34310904 [Abstract] [Full Text] [Related]
31. Comparison of Cerebral Blood Flow in Regions Relevant to Cognition After Enzalutamide, Darolutamide, and Placebo in Healthy Volunteers: A Randomized Crossover Trial. Williams SCR, Mazibuko N, O'Daly O, Zurth C, Patrick F, Kappeler C, Kuss I, Cole PE. Target Oncol; 2023 May 22; 18(3):403-413. PubMed ID: 37103658 [Abstract] [Full Text] [Related]
32. Darolutamide in hormone-sensitive and castration-resistant prostate cancer. Palmieri VE, Roviello G, D'Angelo A, Casadei C, De Giorgi U, Giorgione R. Expert Rev Clin Pharmacol; 2021 May 22; 14(5):535-544. PubMed ID: 33685318 [Abstract] [Full Text] [Related]
34. Adverse Events and Androgen Receptor Signaling Inhibitors in the Treatment of Prostate Cancer: A Systematic Review and Multivariate Network Meta-analysis. Cao B, Kim M, Reizine NM, Moreira DM. Eur Urol Oncol; 2023 Jun 22; 6(3):237-250. PubMed ID: 36682938 [Abstract] [Full Text] [Related]
35. A systematic review and meta-analysis on non-metastatic castration resistant prostate cancer: The radiation oncologist's perspective. Ingrosso G, Bottero M, Becherini C, Caini S, Alì E, Lancia A, Ost P, Sanguineti G, Siva S, Zilli T, Francolini G, Bellavita R, Aristei C, Livi L, Detti B. Semin Oncol; 2022 Oct 22; 49(5):409-418. PubMed ID: 36192243 [Abstract] [Full Text] [Related]
36. Cost-effectiveness of enzalutamide versus apalutamide versus androgen deprivation therapy alone for the treatment of metastatic castration-sensitive prostate cancer in Canada. Saad F, Chilelli A, Hui B, Muratov S, Ganguli A, North S, Shayegan B. J Med Econ; 2022 Oct 22; 25(1):583-590. PubMed ID: 35469527 [Abstract] [Full Text] [Related]
37. Efficacy and safety outcomes of darolutamide in patients with non-metastatic castration-resistant prostate cancer with comorbidities and concomitant medications from the randomised phase 3 ARAMIS trial. Fizazi K, Shore ND, Smith M, Ramos R, Jones R, Niegisch G, Vjaters E, Wang Y, Srinivasan S, Sarapohja T, Verholen F. Eur J Cancer; 2023 Oct 22; 192():113258. PubMed ID: 37660438 [Abstract] [Full Text] [Related]
40. Clinical Development of Darolutamide: A Novel Androgen Receptor Antagonist for the Treatment of Prostate Cancer. Fizazi K, Smith MR, Tombal B. Clin Genitourin Cancer; 2018 Oct 22; 16(5):332-340. PubMed ID: 30197098 [Abstract] [Full Text] [Related] Page: [Previous] [Next] [New Search]